-
)
The U.S. life sciences industry – spanning biotechnology firms, pharmaceutical manufacturers, and research organizations – is facing unprecedented headwinds in 2025 due to new tari ... -
)
The antibody-drug conjugate (ADC) development arena is experiencing a tumultuous phase marked by strategic pivots, trial disappointments, high-stakes legal clashes, and encouraging ... -
)
Isomorphic Labs, an AI-first drug design and development company spun out from Google DeepMind, has announced a landmark $600 million funding round to advance its next-generation A ... -
)
In a moment that will undoubtedly reverberate across the biomedical and regulatory community, Dr. Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research (C ... -
)
Antibody-drug conjugates (ADCs) continue to gain traction as a cornerstone of targeted oncology, offering the ability to selectively deliver potent cytotoxins to tumor cells while ... -
)
Facts about AAV producer cell lines Gene therapies hold almost unlimited promise to treat diseases that have a genetic component. Several gene therapies are commercially available, ... -
)
Introduction Antibody-drug conjugates (ADCs) have revolutionized targeted cancer therapy by combining the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic ... -
)
Why it Matters Transferring potency assays is a complex but crucial process in the development and manufacturing of biological products, particularly in the realm of cell and gene ... -
)
Hydrogels, three-dimensional polymeric networks capable of absorbing substantial amounts of water, have emerged as pivotal materials in the realm of drug delivery systems. Their st ... -
)
Introduction Antibody-drug conjugates (ADCs) have emerged as a transformative modality in oncology, enabling the targeted delivery of cytotoxic agents to tumor cells while minimizi ... -
)
Case Overview: A Pioneering Treatment with Unforeseen Longevity In 2004, a four-year-old girl diagnosed with high-risk neuroblastoma was enrolled in an early-phase CAR-T clinical t ... -
)
Breakthrough in Duchenne Gene Therapy Solid Biosciences has announced promising early results from its Phase 1/2 INSPIRE DUCHENNE trial (NCT06138639) evaluating SGT-003, an investi ... -
)
FDA Decision Expected by August 18, 2025 NOVATO, Calif., Feb. 18, 2025 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced that the U.S. Food and Drug Administration (FDA ... -
)
Sarepta Therapeutics: Pioneering Genetic Medicine Sarepta Therapeutics, a biotechnology company headquartered in Cambridge, Massachusetts, is a global leader in precision genetic m ... -
)
The biggest asset for any drug discovery organization is the ability to access and analyze insightful, contextual, and actionable data, which then informs and underpins critical de ... -
)
Event Overview: Antibody Therapeutics Xchange | February 19, 2025 Explore the latest advancements in antibody design, engineering, and optimization. Participants will tackle pressi ... -
)
Optimizing Dose and Leveraging Biomarkers for Enhanced Patient Safety in Immunotherapy Trials HubXchange Immunotherapies brought together almost 40 senior-level scientists and exec ... -
)
Tumor cells have developed sophisticated mechanisms to evade the immune system, posing significant challenges to effective cancer treatment. Recent research has elucidated several ... -
)
The University of Birmingham has launched Europe's first clinical trial investigating the use of an mRNA-based vaccine to combat pancreatic cancer, a significant advance in persona ... -
)
In the rapidly evolving landscape of precision medicine, one of the greatest challenges lies in predicting individual patient responses to therapeutic agents. Drug efficacy and tox ... -
)
The use of machine learning (ML) in the analysis of vast biological datasets is revolutionizing our approach to drug discovery, personalized medicine, and therapeutic outcome predi ... -
)
Farcast Biosciences, a research solutions company and developer of the TruTumor platform—a large fragment, near-native tumor preservation and histo-culture platform enabling precis ... -
)
Nanotechnology, once confined to the realm of theoretical research, is now revolutionizing biomedical science, particularly in cancer diagnostics and therapy. Nanorobots, designed ... -
)
BNT116, developed by BioNTech, is an advanced mRNA-based therapeutic vaccine designed specifically to target non-small cell lung cancer (NSCLC). This vaccine falls within the broad ... -
)
In the dynamic and rapidly evolving field of antibody therapeutics, the ability to identify targets with optimal therapeutic windows is a critical determinant of clinical success. ...
News Xchange
